Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T15:52:15.031Z.
Calculation as of: 2026-10-06T15:52:15.031Z.
Quote observation: 2026-10-06T15:49:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 11bda5a52c13142378ae00f1a27abc282066b453892c652a9842cb594787c7ab
EARNINGS YIELD
N/A
Market Cap
$110.95M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.57M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.33M
Earnings Yield
N/A
TTM Avg
26.36%
3Y Avg
26.36%
5Y Avg
26.36%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MaxCyte, Inc. (MXCT) | $113.55M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.00M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.95M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.25M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.34M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $110.67M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $110.33M | N/A | 26.36% | 26.36% | 26.36% |
| Genelux Corporation (GNLX)vs › | $116.81M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
